Early Detection Research Network


This biomarker is also known as:
  • tumor-amplified and overexpressed sequence 2,
  • discovered on gastrointestinal stromal tumors protein 1,
  • DOG1,
  • Oral cancer overexpressed protein 2,
  • anoctamin-1,
  • FLJ10261,
  • oral cancer overexpressed 2,
  • ORAOV2,
  • ANO1,
  • transmembrane protein 16A (eight membrane-spanning domains),
  • anoctamin 1, calcium activated chloride channel,
  • transmembrane protein 16A,
  • Transmembrane protein 16A,
  • Discovered on gastrointestinal stromal tumors protein 1,
  • TMEM16A,
  • Tumor-amplified and overexpressed sequence 2,
  • TAOS2,


ANO1, or anoctamin-1, is a calcium-activated chloride channel gene overexpressed in many tumors. ANO1 is ubiquitously expressed in epithelia and is thought to be important in epithelial fluid transport.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Under Review


ANO1 is located within the 11q13 amplicon, one of the most frequently amplified chromosomal regions in human cancer. ANO1 is amplified and highly expressed in breast cancer cell lines and primary tumors.

Performance Comment

ANO1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.